Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 218.66M P/E - EPS this Y -4.10% Ern Qtrly Grth -
Income -104.28M Forward P/E -2.02 EPS next Y -12.60% 50D Avg Chg -27.00%
Sales 2.04M PEG - EPS past 5Y - 200D Avg Chg -13.00%
Dividend N/A Price/Book 1.00 EPS next 5Y - 52W High Chg -44.00%
Recommedations 2.80 Quick Ratio 10.37 Shares Outstanding 85.06M 52W Low Chg 60.00%
Insider Own 0.47% ROA -23.34% Shares Float 61.58M Beta -0.69
Inst Own 86.80% ROE -47.11% Shares Shorted/Prior 3.06M/4.86M Price 3.18
Gross Margin - Profit Margin - Avg. Volume 49,669 Target Price 21.14
Oper. Margin -5,403.78% Earnings Date Aug 6 Volume 24,743 Change -2.91%
About Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada. As of June 4, 2024, Fusion Pharmaceuticals Inc. operates as a subsidiary of AstraZeneca AB.

FUSN Chatroom

User Image Whoflungpooh Posted - 1 week ago

$ICCM I've only ever held stock in 1 company that went through the roof overnight and that was Fusion Pharmaceuticals $FUSN .. That was a great day. Hopefully this will do the same.

User Image Biotech2424 Posted - 09/22/24

$MNPR Monopar’s MNPR101-Lu mechanism of action is just like Pluvicto (Top Novartis Radiopharm Drug) and same lutetium-177 warhead. Could take Monopar from $15 million market cap to $1.5 billion. Company barely spends any money and float is small. Diamond in the rough. https://m.youtube.com/watch?v=a4e0NsEbk_U $FUSN $RYZB $CATX

User Image stockmando Posted - 2 months ago

$FUSN $VOR #1.? Hopefully I am wrong.

User Image Stealthfire Posted - 07/30/24

@ians $FUSN

User Image Investfaithfully Posted - 07/24/24

$FUSN ATNM. IS NEXT……..sooooon!

User Image GwilliamG Posted - 06/24/24

@JDinvestments — it’s just $CATX and $ATNM — that’s it!! and ATNM is complicated because of their P3 asset Iomab-B — which would necessitate a much more complicated CVR than what $FUSN did

User Image stockmando Posted - 5 months ago

@Alon_R who is their main competitor in that space? I was looking at chart, and it was looking similar to $FUSN before it plunged from 1.70.

User Image JG101 Posted - 5 months ago

$ATNM is now worth 1/10 of what $FUSN was bought out for yesterday. This anomaly will correct.

User Image JG101 Posted - 5 months ago

$ATNM $FUSN is now delisted after being bought out for over 2 billion. ATNM is next…

User Image Stock_Titan Posted - 5 months ago

$FUSN Acquisition of Fusion Pharmaceuticals Completed https://www.stocktitan.net/news/FUSN/acquisition-of-fusion-pharmaceuticals-9ca5vmtmv16q.html

User Image tradethehalt Posted - 5 months ago

$FUSN trade halt (T12) was alerted to our Members at 7:50pm EDT. Halt price: $21.65 Vol: 6.09M.

User Image HaltTradeAlert Posted - 5 months ago

$FUSN Halt Time: 19:50:00 Issue Symbol: FUSN Reason Code: T12 Last Price: $21.55 Market Cap: $1833042935 Volume: 6081107.0 Relative Volume: 3.95 Shares Float: 85060000 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

User Image Stock_Titan Posted - 05/31/24

$FUSN Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement https://www.stocktitan.net/news/FUSN/fusion-pharmaceuticals-receives-final-court-order-approving-qecwqdd34qn6.html

User Image JoeSpringer Posted - 05/26/24

100Xer As Clean As They Come The Spitting Image of $FUSN New Big Area New Report: https://multibaggersvip.substack.com/p/rare-100xer-clean-as-can-be-50-off

User Image stockmando Posted - 05/25/24

$FUSN And here is the $VOR chart. Similar set up near bottom.

User Image stockmando Posted - 05/25/24

$FUSN Chart back in 2022. When it was $2. $VOR Back than, it was with very similar fundamentals as VOR

User Image stockmando Posted - 05/25/24

$VOR $FUSN same boys behind the scenes. Same chart, same pattern. FUSN IPO at $20. down to $2. and buyout at $21. VOR IPO at ~30. now at $1.60. FUSN buy out 4 years after IPO, VOR currently ~1 year behind. Institutionals owns a lot of shares. 2 catalyst next 6 months

User Image rickinmiami Posted - 05/21/24

$MTTR and $FUSN are both in the same position for investors. Arbitrage on sale. If milestones hit they payout 25% and 15% respectively. If payout happens in 6 months the annual yield is double. I am in both with 2% of portfolio in each. Deal cancelation is the main risk but I think its 10% or less in each. Anyone have clarity on likelihood of hitting all the milestones for bonus payout?

User Image Achouffe Posted - 6 months ago

$LXRX Hope it’s a better investment than $GLYC for them, although I expect them to make a move over there after the interim on uproleselan. I see some parallels with $FUSN here for Lexi. Both Debanne & Artal vested.

User Image GwilliamG Posted - 6 months ago

@FonsieTrader - objectively speaking, this is a grossly undervalued company as compared to it's peers....and the space is HOT! -- $FUSN, $PNT, $CATX, mariana With a late stage asset (Iomab-B) that had knockout Ph3 results it appears to be more of a valuation stand-off between BP and ATNM. I think a well negotiated CVR gets this over the finish line in '24. I'll invite @resume777 , @Karmic to add their take on this as well

User Image Stock_Titan Posted - 6 months ago

$FUSN Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer https://www.stocktitan.net/news/FUSN/fusion-pharmaceuticals-announces-first-patient-dosed-in-the-phase-2-cp7lyk4kf6mm.html

User Image frankyboyz Posted - 6 months ago

$ATNM The radiopharma space has seen a flurry of dealmaking activity in recent months. Anglo-Swedish drugmaker AstraZeneca, $AZN agreed to offer $2.4B to acquire Fusion Pharma, $FUSN, a Canadian biotech focused on a class of cancer treatments called radioconjugates. Actinium could see a massive sales jump from its radiotherapy business. Disclaimer for my posts: http in bio

User Image HUSA_TO_100 Posted - 6 months ago

$ATOS Just Buy & Hold💪 Coz we know this will make a Move like $FUSN one day✅

User Image DonCorleone77 Posted - 6 months ago

$FUSN Fusion Pharmaceuticals reports Q1 EPS (40c), consensus (37c) CEO John Valliant, Ph.D., commented, "In the first quarter, we demonstrated the potential of FPI-2265 to serve as an important new treatment option for patients with mCRPC, presenting interim data from the TATCIST trial at the 2024 AACR Annual Meeting that we believe represent compelling early clinical activity and tolerability data. We look forward to continuing to develop FPI-2265 as the most advanced actinium-based prostate specific membrane antigen targeting therapy and expect to begin a Phase 2 dose optimization trial in the second quarter of this year, followed by a Phase 3 global registrational trial in 2025. In parallel, we are progressing our other clinical-stage programs as part of our diverse portfolio of alpha-emitting RCs."

User Image Stock_Titan Posted - 6 months ago

$FUSN Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates https://www.stocktitan.net/news/FUSN/fusion-pharmaceuticals-reports-first-quarter-2024-financial-results-v9f2ltwwmvat.html

User Image HUSA_TO_100 Posted - 6 months ago

$ATOS Patiently waiting for this to move like $FUSN that got bought out by $AZN last month ✅ #Long 💪

User Image MateoYo Posted - 6 months ago

@nycmax2002 Yes, I had some good fortune with $FUSN. Feel like another of my holdings $CLRB is a target. Several trials have biten me badly lately however, VINC & TCON for example. Good luck & have a good w/e my man.

User Image StockednLoaded Posted - 6 months ago

$IOVA- Price Discovery doesn't start until $27/share Buyout offers don't get looked at until they contain ten 0's. $XBI $DCPH $ALPN AMBRX CBAY $FUSN

User Image Stock_Titan Posted - 04/25/24

$FUSN Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order https://www.stocktitan.net/news/FUSN/fusion-pharmaceuticals-mails-circular-for-special-meeting-of-8b0yg3hpnzo2.html

User Image Gbornste Posted - 04/24/24

@Darkness746262 I’d like to believe we are worth more than $FUSN

Analyst Ratings
TD Cowen Hold Apr 16, 24
RBC Capital Sector Perform Mar 21, 24
Wedbush Neutral Mar 21, 24
Raymond James Market Perform Mar 20, 24
B. Riley Securities Neutral Mar 20, 24
Truist Securities Hold Mar 20, 24
RBC Capital Sector Perform Mar 20, 24
JonesTrading Hold Mar 20, 24
Truist Securities Hold Mar 19, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GANNON STEVEN Director Director Aug 11 Buy 2.03 44,400 90,132 56,400 08/11/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 20 Sell 6.02 1,289 7,760 326,841 04/22/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 11 Sell 6.96 32,849 228,629 328,130 04/13/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 06 Sell 7.55 2,181 16,467 360,979 04/08/22
Valliant John Chief Executive Offi.. Chief Executive Officer Apr 01 Sell 7.74 3,800 29,412 363,160 04/05/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 30 Sell 7.52 300 2,256 366,960 04/01/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 22 Sell 7.5 4,800 36,000 377,560 03/24/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 17 Sell 7.53 3,604 27,138 382,360 03/21/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 14 Sell 7.02 1,500 10,530 385,964 03/16/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 09 Sell 7.04 2,822 19,867 387,464 03/14/22
Valliant John Chief Executive Offi.. Chief Executive Officer Mar 04 Sell 7.08 14,504 102,688 390,286 03/08/22
Valliant John Chief Executive Offi.. Chief Executive Officer Feb 24 Sell 7.46 13,752 102,590 432,383 02/28/22
Valliant John Chief Executive Offi.. Chief Executive Officer Feb 18 Sell 7.83 38,297 299,866 446,135 02/23/22
Valliant John Chief Executive Offi.. Chief Executive Officer Feb 15 Sell 8.1 47,502 384,766 484,432 02/17/22